SNNLive interview with J.J. Finkelstein, President & CEO of RegeneRx Biopharmaceuticals, Inc. at the 4th Annual SeeThruEquity MicroCap Investor Conference 2015 in New York City, NY.

Watch the video interview.

Shareholder letter - Tuesday February 17, 2015

Link to document.

RegeneRx Pipeline

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.

Latest News:

June 2, 2015
Clinical Trial Demonstrates Elevated Thymosin Beta 4 Plasma Levels are Associated with Improvement of Symptoms After Stem Cell Therapy in Patients with Ischemic Heart Failure

May 22, 2015
RegeneRx to Present at 2 Investor Conferences

May 22, 2015
Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology

May 8, 2015
Researchers Report that Long-Term Administration of Thymosin B4 in a Diabetic Animal Model Prevents Progression of Peripheral Neuropathy and Restores Sciatic Nerve Function

May 4, 2015
Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing

April 23, 2015
RegeneRx Receives Notice of Allowance For U.S. Patent For Healing and Reversing Heart and Coronary Vessel Damage After A Heart Attack with TB4